Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 ...
The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback